Effectiveness of methylphenidate in children with co-occurring attention-deficit/hyperactivity disorder (ADHD) and autism - MICAA Trial

Professor Katrina Williams0 个研究点目标入组 40 人开始时间: 2023年11月6日最近更新: 2024年2月5日

适应症

试验速览

暂无简介。

•Each participant (child) must meet all the following criteria to be enrolled in this trial:
•- Is between the ages of 6 - 15 years at the time of enrolment.
•- Has a clinical diagnosis of ADHD and of ASD.
•- Has been taking a stable dose of MPH-IR (i.e. Ritalin 10) for one month prior to trial enrollment.
•- Parent has signed and dated an informed consent form.

•Exclusion criteria will include any of the following:
•- Inability to read or speak sufficient English for parent/guardian to complete assessment tasks.
•- Is currently taking a medication other than MPH-IR (i.e. Ritalin 10) for the purpose of treating ADHD symptoms.
•- Unable to swallow capsules.
•- Has major illness or disability, including but not limited to: epilepsy, major head injury, Fragile X Syndrome or Williams Syndrome, Foetal Alcohol Spectrum Disorder (FASD) or Neonatal abstinence syndrome.
•- Is known to be pregnant.
•- Research team is not confident the child has both an ADHD and ASD diagnosis.
•- Parent/guardian does not consent to contact with the clinician and school.
•- Is deemed by their treating clinician (psychiatrist/paediatrician/GP) to be medically unfit for trial participation.
•- Child’s school is unwilling to participate in outcome assessments.

发起方

Professor Katrina Williams